Add-on Acquisition • Healthcare Services

NIOX Acquires Aerocrine

On May 15, 2015, NIOX acquired healthcare services company Aerocrine for 1.8B SEK

Acquisition Context

This is NIOX’s 1st transaction in the Healthcare Services sector.
This is NIOX’s 0th largest (disclosed) transaction.
This is NIOX’s 1st transaction in Sweden.

Explore All 4611 Add-on Acquisition Healthcare Services Deals - Search the Database Free

M&A Deal Summary
Date	May 15, 2015
Target	Aerocrine
Sector	Healthcare Services
Buyer(s)	NIOX
Deal Type	Add-on Acquisition
Deal Value	1.8B SEK

Target Company

Aerocrine

Solna, Sweden

Aerocrine AB is a medical technology company focused on improving the treatment of patients with inflamed airways. Aerocrine was formed in 1997 and is based in Solna, Sweden.

Explore More Deals

Browse All 215,156 Deals

FILTER BY

Buyer Type (PE or Strategic)
Deal Size ($10M to $10B+)
Sector (60 Sectors)
Deal Type
Geography
& More

Search Free

Buyer Overview 1

Buyer

NIOX

Oxford, United Kingdom

Category	Company
Founded	2006
Sector	Medical Products
Employees	91
Revenue	42M GBP (2024)

DESCRIPTION

NIOX is a provider in the design, development, and commercialization of medical devices for the measurement of FeNO, a biomarker of inflammatory asthma. NIOX was founded in 2006 and is based in Oxford, England.

Deal Context for Buyer	#
Overall	1 of 2
Sector: Healthcare Services	1 of 1
Type: Add-on Acquisition	1 of 2
Country: Sweden	1 of 1
Year: 2015	1 of 2

FOLLOWING DEAL

DATE	TARGET	DEAL TYPE	VALUE
2015-05-18	Prosonix Oxford, United Kingdom Prosonix is a UK specialty pharmaceutical company focused on the development of a range of product candidates for the treatment of asthma and COPD. Prosonix's portfolio is based on its proprietary particle engineering technology and Prosonitron reactor system, which enables precise control of pharmaceutical product crystallisation during manufacture, and subsequent delivery characteristics.	Buy	£100M

DATE

TARGET

DEAL TYPE

VALUE

2015-05-18

Prosonix

Oxford, United Kingdom

Prosonix is a UK specialty pharmaceutical company focused on the development of a range of product candidates for the treatment of asthma and COPD. Prosonix's portfolio is based on its proprietary particle engineering technology and Prosonitron reactor system, which enables precise control of pharmaceutical product crystallisation during manufacture, and subsequent delivery characteristics.

Buy

£100M

Explore Related M&A Activity

Healthcare Services M&A - Add-on Acquisition M&A Deals - Sweden M&A - 2015 M&A